Reich Kristian 4
4 · MoonLake Immunotherapeutics · Filed Feb 29, 2024
Insider Transaction Report
Form 4
Reich Kristian
Chief Scientific Officer
Transactions
- Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-27$55.00/sh−29,491$1,622,005→ 2,957,483 total(indirect: See footnote.) - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-27$55.00/sh−29,431$1,618,705→ 70,071 total - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-28$55.00/sh−31,910$1,755,050→ 2,925,573 total(indirect: See footnote.) - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-28$55.00/sh−28,090$1,544,950→ 41,981 total
Footnotes (2)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.
- [F2]Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.